Occam Places Mark Strobeck on the Board of Windtree
_440x352.avif)
Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders has appointed Mark Strobeck, Ph.D. to its Board of Directors.
Mark comes to Windtree with more than 20 years of richly varied experience in operations, business development, capital raising, and M&A. Currently, he serves as President and CEO, and Board Member of Rockwell Medical, a publicly held healthcare company that develops, manufactures, commercializes, and distributes a portfolio of products for dialysis providers worldwide.
Prior to joining Rockwell in 2022, Mark was a Managing Partner at Aquilo Partners, a life science investment banking firm specializing in M&A and strategic partnering transactions. Previous executive roles have found him at Zyla Lifesciences (acquired by Assertio Therapeutics), Corridor Pharmaceuticals (acquired by AstraZeneca), Topaz Pharmaceuticals (acquired by Sanofi Pasteur), and GSK.
Mark holds a Ph.D. in pharmacology and cell biophysics from the University of Cincinnati.
Recent Placements
Occam Global is a trusted executive search, consulting, and investment partner for leaders and investors shaping the future of life sciences, deep tech, and venture capital. Since 2012, we’ve helped build high-performing teams and advised visionary companies from stealth to public markets. Our success stems from exceptional access to rare talent, deep sector expertise, and a commitment to results guided by elevated ethics and enlightened aggression.